Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment his department has made of the current accessibility of Motor Neurone Disease treatments with reference to new breakthrough drugs like Tofersen.

The Government recognises how important it is that patients with motor neurone disease (MND) are able to benefit from access to new clinically and cost-effective treatments. There are currently no new treatments routinely available to National Health Service patients for MND. The National Institute for Health and Care Excellence is currently evaluating tofersen, a new licensed treatment for SOD-1 MND, and the company is expected to make an evidence submission to support the appraisal in early June 2026.

Relatedly, the Government is investing significantly in MND research, for example via the £8 million EXPERTS ALS trial, with amyotrophic lateral sclerosis, or ALS, being an alternative name for MND, which screens for drugs that have the potential to be successful in clinical trials for people with MND.